Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
995
resultados
Última actualización
29/10/2026 [08:12:00]
Resultados 125 a 150 de 995
Resumen de: WO2026206998A1
Disclosed herein are methods and compositions for determining survival and treatment responsiveness of subjects with ovarian cancer. Specifically, the disclosure is directed to prognostic glucocorticoid receptor activity signatures for ovarian cancer. Also provided are methods for predicting responsiveness to certain cancer therapies (e.g., selective glucocorticoid receptor modulators (SGRMs)).
Resumen de: US20260297486A1
0000 Disclosed herein are 3D culture systems and methods for producing epithelial tubular organoids, such as intestinal organoids. Also disclosed is a screening method that involves contacting elongated epithelial tubes produced from the disclosed systems and methods with a candidate agent, culturing the elongated epithelial tube in a growth medium under growth conditions, and evaluating the elongated epithelial tube for a physiological effect.
Resumen de: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Resumen de: US20260298947A1
0000 A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.
Resumen de: US20260298949A1
0000 Disclosed and claimed are compositions containing a calibrator and a stabilizer, wherein the stabilizer includes Diethylaminoethyl-(“DEAE”) dextran; D-Sorbitol, wherein the D-Sorbitol and DEAE-dextran are in a weight ratio from about 1:1 to about 5:2, a buffer; and a non-ionic surfactant; wherein the stabilizer is essentially free of bovine serum albumin; and wherein the calibrator is stabilized under frozen storage conditions, and remains stable when thawed and kept at temperatures of from about 2° C. to about 10° C. Also disclosed are methods of use of the claimed compositions and kits comprising the claimed compositions.
Resumen de: US20260298917A1
0000 This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Resumen de: US20260297525A1
Disclosed herein are methods of expanding populations of patrolling monocytes in vitro and in vivo for treatment of sickle-cell disease (SCD), reducing pain and vaso-occlusive events in SCD patients, promoting wound healing, reducing tumor metastases, and treating vascular inflammatory conditions in subjects in need thereof.
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: WO2025050066A1
The present disclosure provides compositions for activating TERT expression and methods of using the same for treating or ameliorating aging, aging-related diseases, and neurodegenerative conditions.
Resumen de: US20260294328A1
0000 Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic/Lac ratio from the measured metabolites, wherein a reduced Bic/Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Resumen de: US20260298946A1
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Resumen de: US20260294329A1
0000 A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and/or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and/or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.
Resumen de: US20260297180A1
0000 The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Resumen de: WO2026207251A1
The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).
Resumen de: KR20260143120A
0001a 본원은 LAMP1(Lysosome-Associated Membrane Protein 1) 및 OPTN(Optineurin)을 유효성분으로 포함하는, 신경 퇴행성 질환 진단용 바이오마커 조성물에 관한 것이다.
Resumen de: EP4814494A1
Provided is a method for identifying molecules and compounds involved in the modulation of lipid synthesis and uptake, wherein said molecule or compound blocks or activates SREBP maturation, comprising contacting cells with a molecule or compound to be tested and observing the presence or absence of domains in the endoplasmic reticulum membrane formed by cholesterol esters with cholesterol or, alternately, localizing SREBP proteins within the cell after said contacting, wherein the molecule or compound is identified as an inhibitor of SREBP maturation when ER domains form within the cell or, alternately, SREBP signal is localized more in the endoplasmic reticulum, whereas the molecule or compound is identified as an activator of SREBP maturation when ER domains are absent or, alternately, SREBP signal is localized more in the nucleus or when its target genes are elevated.
Resumen de: KR20260143067A
본 발명은 퇴행성 뇌질환 치료제 스크리닝용 TDP-43 변이체에 관한 것으로, TDP-43의 특정 영역 돌연변이를 통해 병리적 응집체인 아밀로이드 섬유 형성을 안정적으로 유도함으로써 실제 퇴행성 뇌질환의 병리 현상을 정확히 모사하는 질환 모델을 제공할 수 있다. 또한, 1,6-hexanediol에 대한 저항성을 갖는 고체상의 응집체를 형성하여, 액상 응집체의 병리적 고체상 전이를 제어할 수 있는 치료제 후보 물질을 신속하고 효율적으로 선별할 수 있다. 또한, 효모 및 포유동물 세포 시스템을 이용한 다각적 스크리닝을 통해 약물의 효능 및 세포 독성을 동시에 평가할 수 있는 신뢰성 높은 약물 탐색 플랫폼으로 활용할 수 있다.
Resumen de: CN122836330A
0001 本发明公开了一种阿尔茨海默症早筛传感器的制备方法、传感器及早筛方法，可分别制备电极基底与复合前驱液，将前驱液旋涂固化形成光电复合沟道层，经巯基乙酸与活化液表面活化后，孵育固定Aβ42适配体，再通过牛血清白蛋白封闭非特异位点，制得目标传感器。本发明融合光电化学与晶体管传感技术，实现沟道层光敏与生物识别功能一体化，依托光电协同效应放大微弱电势信号，检出限低、检测速度快、能耗低。本发明有效杜绝非特异性干扰，检测特异性与灵敏度优异，制备工艺简单、成本低廉且易于量产，创新了Aβ42检测思路，适配阿尔茨海默症早期低浓度样本筛查，具备极高的临床推广价值。
Resumen de: WO2026200905A1
The present application relates to an antibody specifically targeting α-synuclein and a use of the antibody. The present application also relates to a humanized antibody involved in the antibody and a use of the humanized antibody.
Resumen de: CN122836171A
本发明提供了用于测定外泌体蛋白的试剂在制备用于确定受试者衰老进程、用于在受试者中鉴定无症状期阿尔茨海默病和/或用于在受试者中区分无症状期阿尔茨海默病与正常衰老的试剂盒中的用途，其中，所述外泌体蛋白包括：C1QC、CO9、GP1BB、RSU1、A0A0G2JRQ6和ADA10。本发明基于六种特定外泌体蛋白的表达水平的动态变化速率分析，可精准区分无症状阿尔茨海默病与正常衰老，适用于AD早期筛查、MCI患者分层管理、疾病进展监测及健康体检，具有重要的临床实用价值和应用前景。
Resumen de: CN122832097A
本发明公开了抗神经丝轻链蛋白的单克隆抗体及其应用，属于单克隆抗体技术领域，具体涉及抗神经丝轻链蛋白的单克隆抗体、抗体对及其在检测试剂盒中的应用；该单克隆抗体包括单克隆抗体2H12和单克隆抗体6E7。本发明提供的单克隆抗体具有高度特异性、高结合力和高亲和力，将其应用于制备神经丝轻链蛋白的免疫检测试剂，有助于显著提升免疫检测试剂的热稳定性，增强其抗钩状效应能力，提高对神经丝轻链蛋白的检测灵敏度和精密度，为神经系统疾病的临床诊断提供了可靠的工具。
Resumen de: CN122836331A
本发明涉及生物医药领域，公开了ATP6V0A1 K303琥珀酰化位点的应用，包括ATP6V0A1 K303琥珀酰化位点在制备用于筛选治疗神经退行性疾病的候选药物的试剂盒中的应用、筛选治疗神经退行性疾病的候选药物的体外方法以及用于筛选治疗神经退行性疾病的候选药物的试剂盒，ATP6V0A1蛋白的氨基酸序列如SEQ ID NO:1所示，K303位点为第303位赖氨酸，检测剂包括用于LC‑MS/MS检测修饰肽段NWFVKSuccinylVR的试剂。本发明通过将该位点琥珀酰化修饰水平用于候选药物筛选，使筛选结果与该位点琥珀酰化修饰水平相对应，为筛选使该位点修饰水平升高的候选药物提供技术基础。
Resumen de: CN122832039A
0001 本发明公开了一种靶向补体C5的多肽及其应用和产品，属于多肽制备技术领域。本发明首次提供了一种C5靶向多肽（命名为C548），该多肽可显著抑制炎症状态下膜攻击复合物（MAC）的组装，有效减轻炎症介导的组织损伤，为自身免疫性疾病及其他补体异常相关疾病提供了一种潜在的替代抗体治疗策略。
Resumen de: US20260298944A1
0000 Provided is a method for measuring a polypeptide aggregate in a sample, wherein the method comprises obtaining information regarding a concentration of the polypeptide aggregate in the sample using a calibrator, and the calibrator comprises a complex comprising: an oligopeptide comprising an epitope of the polypeptide aggregate; a hydrophilic polymer chain not comprising the epitope; and a carrier particle.
Nº publicación: CN122831030A 29/09/2026
Solicitante:
博奥生物集团有限公司清华大学
Resumen de: CN122831030A
本申请公开一种微流控卡盒和蛋白标志物检测方法，该微流控卡盒包括依次串联连接的多个试剂储存腔、与最下游试剂储存腔连通的反应腔、设置于相邻腔室之间流道上的控制阀、与反应腔连通的流体转移单元以及与各试剂储存腔连通的通气孔。本申请的微流控卡盒通过外部磁铁引导磁珠依次穿过各腔室完成靶标捕获、清洗、链霉亲和素偶联和核酸连接，仅在最下游腔室与反应腔之间通过流体转移单元实现液体转移以复溶冻干试剂并进行核酸扩增和信号检测。结构简单，无需精密泵阀，降低了制造成本和操作复杂度。封闭式设计杜绝交叉污染，且通用性强，仅需更换检测抗体即可适配不同靶标蛋白。
BOPI
Sede Electrónica
